Policy Briefings

Pluri Expands CDMO Manufacturing Agreement with Remedy Cell Following GMP Milestone

mAbxience Gains FDA Approval for Two Denosumab Biosimilars with Amneal

FUJIFILM Completes Antibody CDMO Facility in Japan with 10,000L Bioreactor Capacity

Symbiosis Manufactures First 10,000-Vial Batch at New Stirling Facility

Samsung Biologics Acquires GSK’s Rockville Site for $280M, Securing First U.S. Manufacturing Base

Minaris Partners with CGT Catapult to Advance Viral Vector Manufacturing Technologies

AtomVie Global Radiopharma Partners with Ionetix to Secure Actinium-225 Supply

Lifecore Biomedical Signs CDMO Master Services Agreement with Global Pharma Customer

The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025

INCOG BioPharma Services Commits $200M to Expand Injectable Manufacturing in Indiana

Halo Pharma Expands Whippany Site with Gerteis Macro-Pactor® for Solid Dose Manufacturing

Alcami Corporation Adds Fifth GMP-Qualified Sterile Fill-Finish Line in North Carolina

Ayrmid Expands RoslinCT Partnership with Commercial Supply Deal for Omisirge®

PharmaLogic Supplies First Cohort Doses for Ratio Therapeutics’ ATLAS Radiopharmaceutical Trial

uBriGene Biosciences Rebrands Lentiviral Platform as LVV Turbo™ with up to 5x Higher Titers

Gaelic Laboratories Acquires Athlone Laboratories to Expand Beta-Lactam Manufacturing Capacity

PolyPeptide Group Forms Strategic Alliance with Lupin Manufacturing Solutions to Strengthen Peptide Supply Chain

TNAX Biopharma Announces Collaboration with Chime Biologics for Development of TNAX103 Antibody